Goldman Sachs: Raises InnoCare Pharma (09969.HK) target price to HK$23.16, rating "Buy"

Zhitong Finance APP has learned that Goldman Sachs released a research report stating that InnoCare Pharma's (09969.HK) total revenue for the third quarter was higher than the bank's expectations. The bank raised the 12-month target price for its H shares from HK$22.71 to HK$23.16, and raised the target price for InnoCare Pharma's (688428.SH) A shares from RMB 37.93 to RMB 38.68, with a "Buy" rating.